ORCHESTRA BIOMED HOLDI

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

08 авг 2023 07:30:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

26 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

07 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire

Orchestra BioMed to Present at the Jefferies Global Healthcare Conference

01 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

12 май 2023 08:15:18 Источник Nasdaq GlobeNewswire

Orchestra BioMed to Present at Upcoming Investor Conferences

07 мар 2023 07:00:01 Источник Nasdaq GlobeNewswire

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

24 фев 2023 07:00:00 Источник Nasdaq GlobeNewswire